Akebia Therapeutics, Inc. (AKBA) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Akebia is a commercial-stage biopharmaceutical company focused on kidney disease. Its portfolio includes Auryxia (ferric citrate), which lost U.S. exclusivity in March 2025, and Vafseo (vadadustat), which entered the U.S. market in January 2025 for the treatment of anemia in dialysis-dependent chronic kidney disease (CKD) patients. The company operates as a single segment.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 |
|---|---|---|---|---|
| Total Revenues | $62,472 | $43,648 | $119,808 | $76,255 |
| Net Income (Loss) | $247 | $(8,582) | $6,359 | $(26,567) |
| Operating Income (Loss) | $14,089 | $(8,725) | $27,603 | $(23,660) |
| Cash and Cash Equivalents | $137,308 | $51,870 | As of June 30, 2025 | |
| Long-Term Debt (Net) | $47,062 | $38,693 | As of June 30, 2025 | |
| Stockholders' Equity | $29,224 | $(49,185) | As of June 30, 2025 |
Revenue Breakdown (Q2 2025): Product revenue was $60.5 million (Vafseo: $13.3M; Auryxia: $47.2M). License and collaboration revenue was $2.0 million.
Operating Expenses (Q2 2025): R&D was $11.0 million; SG&A was $26.6 million.
Material Changes vs. Prior Period
- Profitability Turnaround: The company reported net income of $0.2 million for Q2 2025, compared to a net loss of $8.6 million in Q2 2024. This shift was driven by increased revenues and the cessation of intangible asset amortization for Auryxia (fully amortized as of Dec 31, 2024).
- Revenue Growth: Total revenue increased 43% year-over-year to $62.5 million, primarily due to the commercial launch of Vafseo in January 2025 and increased Auryxia sales volumes prior to generic competition.
- Loss of Exclusivity (LoE): Auryxia lost U.S. exclusivity in March 2025. The company has begun selling an authorized generic version through a partner to mitigate revenue decline.
- Financing Activity: In Q1 2025, the company completed a public offering raising approximately $48.1 million net and drew down the final tranche ($10M) of its BlackRock credit facility. Cash balances increased significantly from $51.9 million (Dec 2024) to $137.3 million (June 2025).
- Non-Cash Items: A significant non-cash expense of $7.0 million was recorded for the change in fair value of warrant liability in Q2 2025, compared to a gain of $2.3 million in the prior year.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash resources ($137.3M) and expected revenues are sufficient to fund operations for at least 12 months from the filing date.
- Vafseo Expansion: The company is pursuing label expansion for Vafseo to include non-dialysis dependent CKD patients. It aims to initiate the VALOR Phase 3 cardiovascular outcome study by the end of 2025.
- Auryxia Outlook: Future revenue depends on maintaining contracts with dialysis organizations and the pricing of generic competitors. The company notes that reimbursement dynamics (ESRD bundle) may slow revenue decline compared to typical LoE scenarios.
- Debt Covenants: The BlackRock Credit Agreement requires maintaining either $15.0 million in cash or $150.0 million in trailing twelve-month revenue. The company is currently compliant.
- Material Weakness: The company identified a material weakness in internal controls over financial reporting related to inventory accounting and sales forecasting as of December 31, 2024. Remediation efforts are ongoing, and disclosure controls were deemed ineffective as of June 30, 2025.
- Regulatory Risks: Risks include potential FDA delays due to government workforce reductions, challenges in obtaining label expansion, and ongoing patent opposition proceedings in India and Europe.
Investor Verification Checklist
- Inventory Valuation: Verify the accuracy of inventory reserves and the remediation of the material weakness regarding sales forecasting and excess inventory classification.
- Auryxia Revenue Trajectory: Monitor post-LoE sales data to assess the impact of generic competition and the effectiveness of the authorized generic strategy.
- Vafseo Adoption Rates: Track uptake among large dialysis organizations (DaVita, Fresenius, USRC) to validate revenue projections for the new product.
- Debt Service Capacity: Confirm continued compliance with BlackRock covenants, specifically the $15M cash minimum or $150M revenue threshold.
- Warrant Liability Volatility: Assess the impact of stock price fluctuations on the fair value of warrant liabilities, which significantly impacts reported net income/loss.
- Regulatory Timeline: Verify the status of the VALOR study initiation and FDA Type-C meeting outcomes for Vafseo label expansion.